Synthesis and anti-tumor activity of imidazopyrazines as TAK1 inhibitors
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Seok Jong | - |
dc.contributor.author | Lee, Jung Wuk | - |
dc.contributor.author | Chung, Shin Hyuck | - |
dc.contributor.author | Jang, Sun Young | - |
dc.contributor.author | Choi, Jaeyul | - |
dc.contributor.author | Suh, Kwee Hyun | - |
dc.contributor.author | Kim, Young Hoon | - |
dc.contributor.author | Ham, Young Jin | - |
dc.contributor.author | Min, Kyung Hoon | - |
dc.date.available | 2019-05-28T01:38:02Z | - |
dc.date.issued | 2019-02 | - |
dc.identifier.issn | 0223-5234 | - |
dc.identifier.issn | 1768-3254 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/18245 | - |
dc.description.abstract | Transforming growth factor-beta activated kinase-1 (TAK1) is a potential therapeutic target for cancers and inflammatory diseases. We synthesized a series of novel imidazopyrazine derivatives, which were found to exhibit potent inhibitory effect against TAK1. Compound 22a, which possesses a good pharmacokinetic profile, showed excellent in vitro kinase activity and significant in vivo efficacy in mice xenografted with SW620, a KRAS-dependent colon cancer cell line. (C) 2018 Elsevier Masson SAS. All rights reserved. | - |
dc.format.extent | 11 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER | - |
dc.title | Synthesis and anti-tumor activity of imidazopyrazines as TAK1 inhibitors | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.ejmech.2018.12.025 | - |
dc.identifier.bibliographicCitation | EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, v.163, pp 660 - 670 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000458597300049 | - |
dc.identifier.scopusid | 2-s2.0-85058539198 | - |
dc.citation.endPage | 670 | - |
dc.citation.startPage | 660 | - |
dc.citation.title | EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | - |
dc.citation.volume | 163 | - |
dc.type.docType | Article | - |
dc.publisher.location | 프랑스 | - |
dc.subject.keywordAuthor | TAK1 | - |
dc.subject.keywordAuthor | Imidazopyrazine | - |
dc.subject.keywordAuthor | Colon cancer | - |
dc.subject.keywordPlus | ACTIVATED KINASE 1 | - |
dc.subject.keywordPlus | I-KAPPA-B | - |
dc.subject.keywordPlus | DISCOVERY | - |
dc.subject.keywordPlus | PROTEIN | - |
dc.subject.keywordPlus | MAPKKK | - |
dc.subject.keywordPlus | VITRO | - |
dc.subject.keywordPlus | IL-1 | - |
dc.subject.keywordPlus | IDENTIFICATION | - |
dc.subject.keywordPlus | OPTIMIZATION | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.